U.S. Earnings Preview: Before Market Open Sept. 30
Dow Jones2026/09/30 09:30This article was automatically generated by Dow Jones using technology from Automated Insights.
The following companies are among those expected to report their latest financial results before the market opens.
Jabil Inc.'s fourth-quarter EPS is forecast at $3.39, compared with $1.99 in the prior-year period. Adjusted EPS is forecast at $4.05.
FactSet Research Systems Inc.'s fourth-quarter EPS is forecast at $3.88, compared with $4.03 in the prior-year period. Adjusted EPS is forecast at $4.35.
Conagra Brands Inc.'s first-quarter EPS is forecast at 29 cents, compared with 34 cents in the prior-year period. Adjusted EPS is forecast at 28 cents.
Cal-Maine Foods Inc.'s first-quarter EPS is forecast at a loss of 77 cents, compared with net income of $4.12 per share in the prior-year period.
Generated from Dow Jones Calendar Live with data from Dow Jones and Factset.
(END) Dow Jones Newswires
September 30, 2026 05:30 ET (09:30 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
KS Industry holds extraordinary shareholder meeting, elects directors
KS Industry held an extraordinary shareholder meeting on Oct. 8, 2026. Shareholders passed resolutions to appoint Kim In-gyeom as an internal director. Approval was also secured to appoint Chen Yang as an internal director. Resolutions to appoint Kim Woo-joon, Cha Haeng-jeon as independent directors were adopted. The votes authorized these board appointments; the filing did not confirm the appointments have been implemented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KS Industry Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900252), on October 08, 2026, and is solely responsible for the information contained therein.
Pfizer (PFE.US) Tukysa approved in the United States for first-line breast cancer treatment
Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor, Tukysa (tucatinib), as part of a combination regimen for first-line maintenance treatment of a certain type of breast cancer.
Veteran Danny Deep from General Dynamics appointed as the next CEO
Singapore stock index drops over 2%
Crypto prices
More
